Phenotypic and Genomic Analyses of *Burkholderia stabilis* Clinical Contamination, Switzerland

Helena M.B. Seth-Smith, Carlo Casanova, Rami Sommerstein, Dominik M. Meinel,[1]
Mohamed M.H. Abdelbary,[2] Dominique S. Blanc, Sara Droz, Urs Führer, Reto Lienhard, Claudia Lang,
Olivier Dubuis, Matthias Schlegel, Andreas Widmer, Peter M. Keller,[3] Jonas Marschall, Adrian Egli

A recent hospital outbreak related to premoistened gloves used to wash patients exposed the difficulties of defining *Burkholderia* species in clinical settings. The outbreak strain displayed key *B. stabilis* phenotypes, including the inability to grow at 42°C; we used whole-genome sequencing to confirm the pathogen was *B. stabilis*. The outbreak strain genome comprises 3 chromosomes and a plasmid, sharing an average nucleotide identity of 98.4% with *B. stabilis* ATCC27515 BAA-67, but with 13% novel coding sequences. The genome lacks identifiable virulence factors and has no apparent increase in encoded antimicrobial drug resistance, few insertion sequences, and few pseudogenes, suggesting this outbreak was an opportunistic infection by an environmental strain not adapted to human pathogenicity. The diversity among outbreak isolates (22 from patients and 16 from washing gloves) is only 6 single-nucleotide polymorphisms, although the genome remains plastic, with large elements stochastically lost from outbreak isolates.

Burkholderia is a diverse genus of gram-negative bacteria, with isolates identified from a variety of environments, and ever more species being identified and classified. Whereas some *Burkholderia* species are associated with bioremediation potential and antimicrobial and antifungal production, others are animal and human pathogens that generally fall within the *B. cepacia* complex (Bcc) (*1*). *Burkholderia* bacteria have large, flexible, multi-replicon genomes, a large metabolic repertoire, various virulence factors, and inherent resistance to many antimicrobial drugs (*2,3*).

An outbreak of *B. stabilis* was identified among hospitalized patients across several cantons in Switzerland during 2015–2016 (*4*). The bacterium caused bloodstream infections, noninvasive infections, and wound contaminations. The source of the infection was traced to contaminated commercially available, premoistened washing gloves used for bedridden patients. After hospitals discontinued use of these gloves, the outbreak resolved.

Many instances of Bcc strain contamination of medical devices and solutions have been described (*4*), including an outbreak in Korea associated with a 0.5% chlorhexidine solution (*5*). *B. stabilis* also has been identified in nosocomial infections (*6–8*).

We conducted in-depth characterization of the *B. stabilis* strain from the Switzerland outbreak by using clinical methods and whole-genome sequencing (WGS). We generated a complete draft genome by combining short- and long-read genomic data and compared it to other outbreak isolates to provide a complete genomic assessment of this strain. We provide a thorough comparative genomic analysis of this outbreak strain.

Methods

Bacterial Isolate Collection
Isolates were collected from 22 patients (labeled 1–22) and 16 contaminated washing gloves (labeled A–P) across Switzerland during the outbreak (*4*). For comparison, we

Author affiliations: University Hospital Basel, Basel, Switzerland
(H.M.B. Seth-Smith, D.M. Meinel, A. Widmer, A. Egli); University of
Basel, Basel (H.M.B. Seth-Smith, D.M. Meinel, A. Egli); University
of Bern, Bern, Switzerland (C. Casanova, S. Droz); Bern
University Hospital, Bern (R. Sommerstein, J. Marschall);
Lausanne University Hospital, Lausanne, Switzerland
(M.M.H. Abdelbary, D.S. Blanc); Biel Hospital, Biel, Switzerland
(U. Führer); ADMED, La Chaux-de-Fonds, Switzerland
(R. Lienhard); Viollier AG, Allschwil, Switzerland (C. Lang,
O. Dubuis); Cantonal Hospital St. Gallen, St. Gallen, Switzerland
(M. Schlegel); Swissnoso, National Center for Infection
Prevention, Bern (M. Schlegel, A. Widmer, J. Marschall);
University of Zurich, Zurich, Switzerland (P.M. Keller)

[1]Current affiliation: Genetics and Genomics at Roche, Basel,
Switzerland.

[2]Current affiliation: RWTH Aachen University Hospital, Aachen,
Germany.

[3]Current affiliation: University of Bern, Bern, Switzerland

collected 14 unrelated *Burkholderia* spp. patient isolates in Switzerland (labeled O-1 through O-14; Appendix 1 Table 1, https://wwwnc.cdc.gov/EID/article/25/6/17-2119-App1. xlsx). We obtained a control strain, *B. stabilis* ATCC27515 BAA-67, isolated in 1993 from sputum of a patient with cystic fibrosis in Belgium, from the American Type Culture Collection (ATCC, https://www.atcc.org).

Clinical Diagnostics

We performed routine identification using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry and biochemical species identification. For MALDI-TOF mass spectrometry, we used Biotyper MBT Smart (Bruker Corporation, https://www.bruker.com) with flexControl and MBT Compass version 4.1 software. We considered scores >2.0 high confidence identification and scores of 1.7–2.0 low confidence identification. We used VITEK 2 gram negative identification card (bioMérieux, https://www.biomerieux.com) for biochemical species identification. Phenotypic antimicrobial resistance profiles were determined using disk diffusion. We interpreted breakpoints according to Clinical and Laboratory Standards Institute (9) standards for Bcc (ceftazidime, trimethoprim/sulfamethoxazole, and meropenem) or *Enterobacteriaceae* (aminoglycosides, ciprofloxacin, piperacillin/tazobactam, and other β-lactams). We used *Xba*I to digest DNA before using previously described pulsed-field gel electrophoresis (PFGE) molecular typing principles (10). We used GelCompar (Applied Maths, http://www.applied-maths.com) to analyze PFGE results.

Cellular Fatty Acid Analysis

We prepared and derivatized cellular fatty acids from outbreak isolates 7, 13, and O, with control strain *Pseudomonas aeruginosa* strain ATCC27853, as previously described (11). We performed chromatography on an HP 6890 gas chromatograph (Hewlett Packard Enterprise, https://www.hpe.com) and analyzed data in SHERLOCK MIS version 6.2 (Midi Inc., http://midi-inc.com).

Genome Sequencing, Assembly, Annotation, and Mapping

We extracted DNA using EZ1 Advanced XL (QIAGEN, https://www.qiagen.com) or Wizard Genomic DNA Purification kit (Promega, https://www.promega.com) and then sequenced it on the Illumina MiSeq platform (https://www.illumina.com) following Nextera XT library creation within the Division of Clinical Microbiology, University Hospital Basel (300-bp paired-end reads) or the Unit of Genomics of the Institute of Microbiology, Lausanne University Hospital (150-bp paired-end reads). We mapped data against the genome of *B. cepacia* ATCC25416 (GenBank accession nos. CP007746–8) for quality control and coverage determination (Appendix 1 Table 1). We sequenced

DNA from outbreak isolate 5 on a PacBio RS II platform (Pacific Biosciences, https://www.pacb.com) with 1 SMRT cell at the Functional Genomics Centre, Zurich. We submitted read data for all samples to the European Nucleotide Archive under project nos. PRJEB18658 and PRJEB19203 (data previously analyzed; 12).

We used CLC Genomics Workbench 9 (https://clc-genomics-workbench.software.informer.com/9.0) to assemble Illumina reads from outbreak isolate E (1,736 contigs; assembly length 8,816,302 bp) and from unrelated isolates. We processed PacBio reads with CLC Genomics Workbench 9 using an error correction of 30 or 50 and assembled resulting reads or used them to correct the Illumina assembly of E. We used Spades version 3.10.0 (13) to assemble the PacBio reads with Illumina reads from isolates E or 5. We manually compared assemblies in Artemis and ACT (14,15) to circularize and split chromosomes 1 and 2 according to the genome of *B. stabilis* BAA-67 (GenBank accession nos. CP016442–4) (16). We found chromosome 3 is a single contig that was not obviously circularizable. We used Prokka version 1.11 (17) for automated annotation and manually curated coding sequences (CDSs) by using Artemis and ACT. We submitted the genome draft to ENA under accession no. ERZ480954.

We performed mapping in CLC Genomics Workbench 9, which we also used to generate k-mer trees (18) using default parameters. For single-nucleotide polymorphism (SNP) phylogenies, we used variant calling with 5× minimum coverage, 5 minimum count, and 70% minimum frequency and created SNP trees with 5× minimum coverage, 5% minimum coverage, 0 prune distance, and multinucleotide variants.

Database and Genome Comparisons

We used multilocus sequence typing (MLST; https://cge.cbs.dtu.dk/services/MLST) to identify alleles from assemblies of isolate E and unrelated *Burkholderia* spp. (19) and compared these against Bcc MLST databases (https://pubmlst.org/bcc) (20) for species designation. We performed average nucleotide identity (ANI) determination using the ANI calculator (http://enve-omics.ce.gatech.edu/ani) (21), and digital DNA-DNA hybridization (dDDH) with GGDC2.1 (http://ggdc.dsmz.de/distcalc2.php) (22). We used antiSMASH version 4.0.0 (https://antismash.secondarymetabolites.org) (23) to predict gene clusters involved in antimicrobial resistance and secondary metabolite production.

Results

Clinical and Major Fatty Acid Characterization

We analyzed outbreak and unrelated *Burkholderia* spp. isolates by PFGE (Appendix 2 Figure 1, https://wwwnc.

cdc.gov/EID/article/25/6/17-2119-App2.pdf). PFGE patterns of outbreak isolates from patients and washing gloves formed a cluster separate from the unrelated isolates. Outbreak isolates shared 75.7% similarity by Pearson correlation analysis; previous studies used a value of 80% for outbreak grouping (24).

We conducted MALDI-TOF mass spectrometry on 12 outbreak isolates and identified *B. cepacia* group (n = 4), *B. stabilis* (n = 4), *B. multivorans* (n = 2), *B. cenocepacia* (n = 1), and *B. pyrrocinia* (n = 1) with scores of 1.88–2.21. Because MALDI-TOF mass spectrometry is known to misidentify Bcc species (25), we used VITEK 2 to conduct biochemical testing on isolates from 3 patients and 1 washing glove and identified either Bcc group (scores of 91%–95%) or *Acinetobacter lwoffii* (scores of 86%–91%).

Our outbreak isolates and control strain shared a defining characteristic of *B. stabilis*, the inability to grow at 42°C (26). Using VITEK 2, we saw 2 other key characteristics of *B. stabilis* in the outbreak strain, absence of β-galactosidase activity and inability to oxidize sucrose (Table 1). In contrast to other *B. stabilis* strains, VITEK 2 showed our strain was negative for adonitol acidification, ornithine decarboxylase, and lysine decarboxylase. Phenotypic identification of *Burkholderia* spp. often is a tedious process (26), with high rates of misidentification because of false negative reporting by VITEK 2 (29). Clinical standard identification on the VITEK 2 runs up to 16 hours, but *Burkholderia* phenotypes can take up to 7 days to develop. Our subsequent genome analysis identified genes encoding ornithine decarboxylase and lysine decarboxylase in the outbreak strain.

Cellular fatty acid profiling of 3 outbreak isolates showed profiles highly similar to the reference strains *B. stabilis* and *B. cepacia* (26,30), and expectedly distinct from control strain *P. aeruginosa* strain ATCC27853 (Appendix 1 Table 2; Appendix 2 Figure 2). Together, these assays identified the outbreak strain as a member of the genus *Burkholderia* within Bcc but did not enable a firm species-level identification.

Identification of Outbreak Isolate Clade in Bcc

We conducted WGS on 22 patient isolates and 16 isolates from washing gloves. We compared a full-length 16S rRNA gene sequence derived from the genome assembly of isolate E against the National Center for Biotechnology Information nucleotide sequence database using blastn (http://blast.ncbi.nlm.nih.gov). We identified 2 top hits, both sharing 1,520 out of 1,521 nt identities, *B. pyrrocinia* DSM10685, and *B. stabilis* BAA-67. Many other Bcc species shared >99% nucleotide identity, including *B. stagnalis* MSMB735WGS, *B. cenocepacia* AU1054, *B. cenocepacia* J2315, *B. ambifaria* AMMD, and *B. lata* 383. We mapped the WGS data of all outbreak isolates against a draft assembly of isolate E and found 99%–100% coverage from all isolates, but only 60%–75% coverage from unrelated isolate sequences (Appendix 1 Table 1). K-mer analysis of outbreak and unrelated *Burkholderia* isolates showed a separate cluster of outbreak isolates (Appendix 2 Figure 3).

Table 1. Biochemistry of *Burkholderia stabilis* outbreak strain from 3 patient isolates and 1 environmental isolate collected from hospitals in Switzerland, 2015–2016*

Reaction	Result	No. outbreak strains with result	Expected *B. stabilis* result†
Saccharose, sucrose‡	–	4	–
β-galactosidase‡	–	4	–
Maltose acidification	+	3	+
Adonitol acidification	–	4	+
Ornithine decarboxylase	–	4	+
Lysine decarboxylase	–	4	+
D-mannitol	–	4	+
D-glucose	+	4	+
D-cellobiose	+	4	+
Malonate	–	4	+
D-sorbitol	–	4	+
Urease	–	4	+ or –

*Performed using VITEK 2.
†From (26,28).
‡Specific discriminatory test for *B. stabilis*.

Table 2. Genome comparisons of *Burkholderia stabilis* outbreak strain CH16 from Switzerland against *Burkholderia* reference strains*

Reference genome	Genomovar	GenBank accession nos.	ANI,† 1-way,%	dDDH,‡ formula 2	Probability dDDH ≥70%	% G+C difference
B. stabilis ATCC BAA-67	IV	CP016442–4	98.4	87.8	94.98	0.08
B. pyrrocinina DSM10685	IX	CP011503–6	92.9	49.4	17.44	0.17
B. stabilis LA20W§	IV	GCA_001685505.1	92.5	49.3	17.3	0.16
B. lata 383		NC_007509–11	91.4	44.7	7.72	0.12
B. cepacia ATCC25416	I	NZ_CP012981–3	91.3	44.5	7.52	0.37
B. cenocepacia J2315	III	AM747720–3	91.1	44	6.68	0.55
B. ambifaria AMMD	VII	NZ_CP009798–800	89.8	39.9	2.65	0.44
B. latens AU17928		CP013435–8	88.8	37	1.22	0.03
B. dolosa AU0158	VI	CP009793–5	88.8	37.2	1.27	0.66
B. vietnamensis LMG10929	V	CP009629–32	88.5	36.2	0.97	0.48
B. multivorans DDS 15A-1	II	CP008728–30	88.3	36	0.89	0.25
B. multivorans BAA247	II	CP009830–2	88.1	35.3	0.71	0.9

*ANI, average nucleotide identity; dDDH, digital DNA-DNA hybridization.
†Species cutoff 95%.
‡Species cutoff 70%.
§From these results, strain LA20W should not be classified as *B. stabilis*.

Identification of New *B. stabilis* Strain

We used MLST to extract alleles from the genome draft to obtain a new sequence type (ST), 1095, with the following genes: *atpD* (380, new), *gltB* (456), *gyrB* (213), *lepA* (70), *phaC* (348, new), *recA* (109), *trpB* (173). The top matches to this MLST profile are all *B. stabilis* isolates sharing ≤4 of the 7 alleles. The matching isolates are from Canada, which had 4 matching alleles; and Czechia, Serbia, China, France, Italy, and the United Kingdom, each with 2 matching alleles, including the *B. stabilis* type strain ATCC27515 BAA-67.

We used ANI calculations of genomic relatedness to compare the isolate E genome draft to a comprehensive panel of sequenced Bcc strains (Table 2). *B. stabilis* BAA-67 is the most closely related with an ANI of 98.4%, which is above the species cutoff of 95% (*31*). In addition, dDDH comparing the outbreak strain to the Bcc panel showed that the maximum score of the outbreak genome is with *B. stabilis* BAA-67 at 84.2%, with the classic species threshold at 70%. These genomic parameters currently are the most robust for species designation (*32–34*) and we are confident that the outbreak strain belongs to the species *B. stabilis*. The high dDDH score might reflect the high genome conservation within this species, giving it its name (*26*).

Description of Draft of *B. stabilis* Strain CH16

A hybrid assembly of PacBio and Illumina data resulted in an improved, high-quality genome draft (*35*) of the outbreak strain, named CH16 because it occurred in Switzerland in 2016. This draft comprises 1 contig for each of the 3 chromosomes. Comparison with the genome of *B. stabilis* BAA-67 (*16*) showed that the genomes are syntenic with the exception of a rearrangement on chromosome 1 between the rRNA operons, which might be a real inversion or an assembly artifact in 1 of the genomes (Figure 1). We detected a separate contig representing a predicted plasmid sequence, whereas none was found within strain BAA-67 (J. Bugrysheva, US Centers for Disease Control and Prevention, pers. comm., 2017 Jan 10) (Table 3).

In addition to being large and multireplicon, *Burkholderia* genomes are characterized by the presence of multiple phages, genomic islands, and insertion sequences (IS elements) (*3*). The draft genome CH16 contains many insertions of single or multiple genes relative to strain BAA-67: 16 on chromosome 1; 34 on chromosome 2; and 10 on chromosome 3 (Figure 1). Appendix 1 Table 3 lists regions of difference (RDs).

The *B. stabilis* CH16 genome has a paucity of IS elements. We have identified only 40, including 6 families with copy numbers of 3–12 (Appendix 1 Table 4), that cause disruption of 9 CDSs (Appendix 1 Table 5). CH16 did not appear to be experiencing IS element expansion, which is associated with genome rearrangements, large-

Table 3. General properties of genome draft for *Burkholderia stabilis* strain CH16 from Switzerland*

Property	Value
Draft genome size, bp	8,505,958
Chromosomes	3
Chromosome sizes, bp	3,705,321; 3,499,410; 1,230,432
Plasmid size, bp	70,922
% G+C content	66.3
Predicted CDSs (per chromosome and plasmid)	7,629 (3,402; 3,068; 1,075; 84)
Coding density	86.40%
Average gene length	965 bp
Pseudogenes	20
rRNA operons	6
tRNAs	75
Insertion elements	40

*CDSs, coding sequences.

scale genomic deletions, and niche adaptation (*36–38*), but it has the potential for IS element expansion if it goes through a population bottleneck.

Frameshifts and premature stop codons have created 11 additional pseudogenes (Appendix 1 Table 5). The 20 pseudogenes of CH16 contrast with 142 annotated in the genome of strain BAA-67, indicating that most of the CH16 genome is required for survival in diverse environments and that this strain is not adapting to a pathogenic lifestyle.

RDs and Virulence Factors of *B. stabilis* Strain CH16

Using genome-wide blastn comparisons, we determined that the CH16 genome carries 973 novel CDSs relative to BAA-67 of the total 7,629 CDSs (12.7%; Appendix 1 Table 3), many of which are novel to all *Burkholderia* sequenced to date. Larger insertions containing >40 CDSs are putative phages or integrative and conjugative elements. Smaller insertions of <10 CDSs appear to represent deletions in the BAA-67 strain relative to their common ancestor.

Factors that might contribute to the virulence of CH16 include adhesins and hemaglutinins, including *BSTAB16_1184*, *_5825*, *_5829*, *_5874*, *_6110*, *_6684*, *_6804*, and *_6861*, of which most have homologs in other Bcc strains; and Type II and Type VI secretion systems (*BSTAB16_4657–74*, *_5069–91*, and *_5583–9*). The many regulators within the CH16 genome and the RDs provide additional layers of translational control necessary in a genome of this size. We saw no evidence of the known *Burkholderia* virulence factors cable pilus or *B. cepacia* epidemic strain marker (*36*). The toxins we identified, for example *BSTAB16_5843* containing the HipA domain, are antibacterial toxins rather than virulence factors.

The many efflux pumps found in the CH16 genome might explain its ability to grow in the wash solution, including members of the following families: resistance nodulation and cell division, ATP-binding cassette, small multidrug resistance, multidrug and toxic compound extrusion,

Figure 1. Comparison of the genome of *Burkholderia stabilis* strain CH16 from Switzerland (top bar) with that of *B. stabilis* reference strain BAA-67 (bottom bar). Alternating orange and brown bar sections represent chromosomes 1, 2, 3, and a plasmid. Scale bar indicates identity between the genomes (determined by blastn, http://blast.ncbi.nlm.nih.gov). Colors above the CH16 genome indicate the following: purple, regions of difference between the 2 strains; green, putative integrative and conjugative element; blue, phage; and red, the plasmid.

and major facilitator superfamily. Several secondary metabolite synthesis pathways are predicted: 4 on chromosome 1; 5 on chromosome 2; and 5 on chromosome 3 (Appendix 1 Table 6). Most of these are shared with the BAA-67 reference genome, encoding the ability to produce signaling molecules, siderophores, terpenes, and a bacteriocin, among others.

The plasmid comprises largely novel sequences not seen before within the *Burkholderia* or elsewhere. It carries genes predicted to be involved in conjugation, indicating that it might be a mobile plasmid, such as 1 recently hypothesized in *B. cenocepacia* (*39*). The rest of the plasmid largely comprises genes encoding hypothetical proteins.

Antimicrobial Drug Resistance of *B. stabilis* Strain CH16

We performed phenotypic antimicrobial drug susceptibility testing on a subset of outbreak isolates (Appendix 1 Table 7) and used genomic findings to interpret the results. Breakpoints are not established clinically and are not recommended to guide patient therapy (*40*).

All Bcc isolates are intrinsically resistant to aminoglycosides (*40*), which we confirmed in our isolates. Intrinsic resistance also is described against chloramphenicol and tetracycline (*40*) (not tested) through the presence of efflux pumps. We identified several efflux pumps within the CH16 genome (*BSTAB16_5335–6*, *_4605–6*, and *_7210–1*), none of which are unique to the outbreak strain. Sensitivity to trimethoprim/sulfamethoxazole was a feature of the outbreak isolates; we did not identify trimethoprim/sulfamethoxazole resistance determinants in the draft genome.

Bcc is considered to be intrinsically and clinically resistant to many β-lactams through impermeability and the presence of inducible β-lactamases (*40*). All Bcc isolates tested were resistant to aminopenicillins, carboxypenicillins, and first-generation cephalosporins. Phenotypic resistance to third-generation cephalosporins, ureidopenicillins, and carbapenems was more variable among Bcc. We identified several β-lactamases in the CH16 genome, representing class A (*BSTAB16_4862* and *_4440*), class C (*BSTAB16_6957*), class D (*BSTAB16_5918*), and metallo-

β-lactamases (*BSTAB16_ 3974* and *_5115*), none of which are unique to this strain.

The outbreak isolates are sensitive to ciprofloxacin, in contrast to *B. stabilis* BAA-67, with sporadic resistance seen among other Bcc isolates. Resistance can be associated with efflux (*40*) or specific mutations in *gyrA* (*BSTAB16_1445*). The *gyrA* of CH16 differs from that of strain BAA-67 at I83T and A700S (numbered according to *E. coli*). In general, this strain does not display enhanced antimicrobial resistance compared with other clinical Bcc isolates or *B. stabilis* BAA-67 (*2,41,42*).

Of note, some of the outbreak isolates had anomalous antibiograms, which we confirmed through repeated testing (Appendix 1 Table 7). This finding might relate to colony morphology because several morphotypes were observed during clinical work on the outbreak isolates. This phenomenon is known to occur within *Burkholderia* (*43–46*), resulting from reversible colony morphotype switching (*44*) or stable mutations (*43,46*). Altered genes often are involved in exopolysaccharide production, also causing changes in biofilm production, virulence, resistance, and motility (*43–46*), and might result from stress (*44,45*).

Comparison of Outbreak Isolates

PFGE and k-mer analyses showed that the outbreak isolates cluster. We investigated how related the isolates are by comparing genomes using high-quality SNPs. The SNP phylogeny (Figure 2) indicates a maximum of 6 SNPs between isolates from the outbreak source, in agreement with Abdelbary et al. (*12*). The previously published core genome MLST (cgMLST) phylogeny used the same genome data but indicated up to 18 alleles difference between isolates (*4*), though these are likely artifacts of the methodology (*47*).

Washing glove isolates were located throughout the phylogeny; we observed diversity within a lot number (isolates E–F and L–O), and even within single packets (isolates A, B, and L–O). Patient samples also were found throughout the phylogeny, even those originating from the same city (isolates 5, 7, 9–13 are from a first city; 6, 8, 21,

Figure 2. Phylogeny of outbreak isolates of *Burkholderia stabilis* strain CH16 from Switzerland based on high-quality single nucleotide polymorphisms (SNPs). This phylogeny of all sequenced outbreak isolates might represent a conservative estimate of SNP numbers. Given the large genome size and possible mismapping to repeats, it is difficult to determine the ultimate number of SNPs between samples. This phylogeny was confirmed using several parameters and manual checking of called SNPs. The root was arbitrarily chosen to give the fewest root to tip SNPs (n = 6). Numbers represent isolates from patients; letters represent isolates from washing gloves, located in the root position. Scale bar indicates 1 SNP.

and 22 are from a second city; and 14–20 are from a third city), reflecting trends seen from cgMLST data (*4*).

SNP locations (Appendix 1 Table 8) indicate that, of the 40 nonsynonymous SNPs, 15 are in genes predicted to encode regulators, 6 in transporters, and 3 in flagellin. We could not tell whether these are random mutations or have been subject to selective pressure, but all classes are represented in both glove and patient isolates.

In addition to the SNPs, we saw some large-scale genomic differences. By mapping read data against each individual replicon, we noted that isolates E and 20 do not carry the plasmid, which appears to be a stochastic event because the SNP phylogeny indicates that these isolates are not derived from a common ancestor. Isolates D and E have highly similar PFGE patterns (Appendix 2 Figure 1), suggesting that the plasmid does not affect the PFGE results or was lost during laboratory culture. Patient isolate 22 also shows the loss of the first 52.5 kb of chromosome 3, representing an RD, which this isolate apparently lost spontaneously during the course of the outbreak. Because of this genome plasticity, we hypothesize the CH16 genome was changing even during the course of the outbreak.

Discussion

We provide a thorough and detailed description of a *Burkholderia* sp. outbreak resolved by WGS (*4*) and illustrate

various associated challenges, including morphotype differences, species designation, and a large genome with associated assembly, annotation, and interpretation issues. Defining species within Bcc is notoriously difficult (*26*), whether phenotypically by using biochemical or MALDI-TOF mass spectrometry profiles, genomically by using 16S rRNA gene sequences, or both. WGS provides the most thorough analysis and is increasingly cost and time effective, even compared with sequencing MLST loci, interpretation of which also is complex. We saw anomalies between the phenotype of this *B. stabilis* outbreak strain and those described in the literature (*26,27*) due to shorter than optimal test incubation times in standard clinical phenotyping (*29*).

Several techniques can be used on WGS data to provide phylogenies. K-mer analysis (Appendix 2 Figure 3) provides an indication of clustering, but the branch lengths cannot be relied on to provide a true phylogeny and do not truly reveal relationships within clades. With this technique, a lot of genomic information regarding the coding capacity of the genome is lost. cgMLST compares nucleotide sequences of CDSs common to a group of isolates, linking isolates with the highest numbers of identical alleles. During this process some genomic data necessarily are lost, with information from accessory genes and intergenic regions disregarded. However, both methods can be performed routinely with minimal training to enable rapid visualization of outbreak

clusters. Comparing reads from all outbreak isolates to an assembled draft genome to generate a SNP phylogeny includes all genomic information but requires more computation, time, and expertise.

WGS is the optimal way to determine the detailed relationships between isolates, giving insights into an outbreak and providing a basis from which to develop further typing methods. For future cases, we suggest rapid WGS, extraction of MLST alleles from assemblies for species identification as recommended by Mahenthiralingam et al. (*48*), and cgMLST typing for rapid outbreak identification. SNP detection can be a valuable subsequent step to determine accurate relatedness of isolates.

Bcc bacteria are known to survive in pharmaceutical and disinfectant materials (*1,48,49*). *B. stabilis* strains sharing MLST types can be isolated from the natural environment, hospitals, and patients (*50*), implicating the natural environment as a source of opportunistic *Burkholderia* and emphasizing the versatility of Bcc to survive and grow under diverse conditions. The CH16 genome displays features representative of *Burkholderia* in general; it is large, highly plastic, and contains many novel elements that might be involved in pathogenesis or environmental survival (*36*). The low number of pseudogenes and IS elements indicates that this strain has not undergone niche adaptation, and most likely is an opportunistic pathogen (*36–38*).

The cloud of diversity seen in the SNP phylogeny indicates that the source of the original contamination was not clonal or that several mutations occurred during the incubation of CH16 within the patient washing gloves. The loss of genomic elements, including the plasmid, from some of the isolates, also demonstrates the flexibility and the redundancy within such a large genome. Our study shows the importance of WGS in investigating and resolving this outbreak, which appears to have been caused by an environmental Bcc strain.

Acknowledgments

About the Author

Dr. Seth-Smith works in clinical microbiology at University Hospital Basel, using whole-genome sequencing data to answer questions relating to emerging pathogens, outbreaks, and transmission.

References

1. Depoorter E, Bull MJ, Peeters C, Coenye T, Vandamme P, Mahenthiralingam E. *Burkholderia*: an update on taxonomy and biotechnological potential as antibiotic producers. Appl Microbiol Biotechnol. 2016;100:5215–29. http://dx.doi.org/10.1007/s00253-016-7520-x
2. Nzula S, Vandamme P, Govan JRW. Influence of taxonomic status on the in vitro antimicrobial susceptibility of the *Burkholderia cepacia* complex. J Antimicrob Chemother. 2002;50:265–9. http://dx.doi.org/10.1093/jac/dkf137
3. Burns J. Antibiotic resistance of *Burkholderia* species. In: Coenye T, Vandamme P, editors. *Burkholderia*: molecular microbiology and genomics. Wymondham, England, UK: Horizon Bioscience; 2006. p. 81–91.
4. Sommerstein R, Führer U, Lo Priore E, Casanova C, Meinel DM, Seth-Smith HM, et al. *Burkholderia stabilis* outbreak associated with contaminated commercially-available washing gloves, Switzerland, May 2015 to August 2016. Euro Surveill. 2017;22:pii:17-00213. http://dx.doi.org/10.2807/1560-7917. ES.2017.22.49.17-00213
5. Ko S, An HS, Bang JH, Park SW. An outbreak of *Burkholderia cepacia* complex pseudobacteremia associated with intrinsically contaminated commercial 0.5% chlorhexidine solution. Am J Infect Control. 2015;43:266–8. http://dx.doi.org/10.1016/j.ajic.2014.11.010
6. Otağ F, Ersöz G, Salcioğlu M, Bal C, Schneider I, Bauernfeind A. Nosocomial bloodstream infections with *Burkholderia stabilis*. J Hosp Infect. 2005;59:46–52. http://dx.doi.org/10.1016/j.jhin.2004.06.034
7. Heo ST, Kim SJ, Jeong YG, Bae IG, Jin JS, Lee JC. Hospital outbreak of *Burkholderia stabilis* bacteraemia related to contaminated chlorhexidine in haematological malignancy patients with indwelling catheters. J Hosp Infect. 2008;70:241–5. http://dx.doi.org/10.1016/j.jhin.2008.07.019
8. Wang L, Wang M, Zhang J, Wu W, Lu Y, Fan Y. An outbreak of *Burkholderia stabilis* colonization in a nasal ward. Int J Infect Dis. 2015;33:71–4. http://dx.doi.org/10.1016/j.ijid.2014.12.046
9. Clinical and Laboratory Standards Institute.Performance standards for antimicrobial susceptibility testing (M100–S27). Wayne (PA); The Institute; 2017.
10. Strandén A, Frei R, Widmer AF. Molecular typing of methicillin-resistant *Staphylococcus aureus*: can PCR replace pulsed-field gel electrophoresis? J Clin Microbiol. 2003;41:3181–6. http://dx.doi.org/10.1128/JCM.41.7.3181-3186.2003
11. Osterhout GJ, Shull VH, Dick JD. Identification of clinical isolates of gram-negative nonfermentative bacteria by an automated cellular fatty acid identification system. J Clin Microbiol. 1991;29:1822–30.
12. Abdelbary MMH, Senn L, Moulin E, Prod'hom G, Croxatto A, Greub G, et al. Evaluating the use of whole-genome sequencing for outbreak investigations in the lack of closely related reference genome. Infect Genet Evol. 2018 Apr;59:1–6. http://dx.doi.org/10.1016/j.meegid.2018.01.014
13. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol. 2012;19:455–77. http://dx.doi.org/10.1089/cmb.2012.0021
14. Carver TJ, Rutherford KM, Berriman M, Rajandream MA, Barrell BG, Parkhill J. ACT: the Artemis Comparison Tool.

Bioinformatics. 2005;21:3422–3. http://dx.doi.org/10.1093/bioinformatics/bti553

15. Rutherford K, Parkhill J, Crook J, Horsnell T, Rice P, Rajandream M-A, et al. Artemis: sequence visualization and annotation. Bioinformatics. 2000;16:944–5. http://dx.doi.org/10.1093/bioinformatics/16.10.944

16. Bugrysheva JV, Cherney B, Sue D, Conley AB, Rowe LA, Knipe KM, et al. Complete genome sequences for three chromosomes of the *Burkholderia stabilis* type strain (ATCC BAA-67). Genome Announc. 2016;4:e01294-16. http://dx.doi.org/10.1128/genomeA.01294-16

17. Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics. 2014;30:2068–9. http://dx.doi.org/10.1093/bioinformatics/btu153

18. Larsen MV, Cosentino S, Lukjancenko O, Saputra D, Rasmussen S, Hasman H, et al. Benchmarking of methods for genomic taxonomy. J Clin Microbiol. 2014;52:1529–39. http://dx.doi.org/10.1128/JCM.02981-13

19. Larsen MV, Cosentino S, Rasmussen S, Friis C, Hasman H, Marvig RL, et al. Multilocus sequence typing of total-genome-sequenced bacteria. J Clin Microbiol. 2012;50:1355–61. http://dx.doi.org/10.1128/JCM.06094-11

20. Jolley KA, Maiden MC. BIGSdb: Scalable analysis of bacterial genome variation at the population level. BMC Bioinformatics. 2010;11:595. http://dx.doi.org/10.1186/1471-2105-11-595

21. Goris J, Konstantinidis KT, Klappenbach JA, Coenye T, Vandamme P, Tiedje JM. DNA-DNA hybridization values and their relationship to whole-genome sequence similarities. Int J Syst Evol Microbiol. 2007;57:81–91. http://dx.doi.org/10.1099/ijs.0.64483-0

22. Auch AF, von Jan M, Klenk H-P, Göker M. Digital DNA-DNA hybridization for microbial species delineation by means of genome-to-genome sequence comparison. Stand Genomic Sci. 2010;2:117–34. http://dx.doi.org/10.4056/sigs.531120

23. Weber T, Blin K, Duddela S, Krug D, Kim HU, Bruccoleri R, et al. antiSMASH 3.0—a comprehensive resource for the genome mining of biosynthetic gene clusters. Nucleic Acids Res. 2015;43(W1):W237–43. http://dx.doi.org/10.1093/nar/gkv437

24. Chetoui H, Melin P, Struelens MJ, Delhalle E, Nigo MM, De Ryck R, et al. Comparison of biotyping, ribotyping, and pulsed-field gel electrophoresis for investigation of a common-source outbreak of *Burkholderia pickettii* bacteremia. J Clin Microbiol. 1997;35:1398–403.

25. Fehlberg LC, Andrade LH, Assis DM, Pereira RH, Gales AC, Marques EA. Performance of MALDI-ToF MS for species identification of *Burkholderia cepacia* complex clinical isolates. Diagn Microbiol Infect Dis. 2013;77:126–8. http://dx.doi.org/10.1016/j.diagmicrobio.2013.06.011

26. Vandamme P, Mahenthiralingam E, Holmes B, Coenye T, Hoste B, De Vos P, et al. Identification and population structure of *Burkholderia stabilis* sp. nov. (formerly *Burkholderia cepacia* genomovar IV). J Clin Microbiol. 2000;38:1042–7.

27. Henry DA, Mahenthiralingam E, Vandamme P, Coenye T, Speert DP. Phenotypic methods for determining genomovar status of the *Burkholderia cepacia* complex. J Clin Microbiol. 2001;39:1073–8. http://dx.doi.org/10.1128/JCM.39.3.1073-1078.2001

28. Vandamme P, Holmes B, Vancanneyt M, Coenye T, Hoste B, Coopman R, et al. Occurrence of multiple genomovars of *Burkholderia cepacia* in cystic fibrosis patients and proposal of *Burkholderia multivorans* sp. nov. Int J Syst Bacteriol. 1997;47:1188–200. http://dx.doi.org/10.1099/00207713-47-4-1188

29. Zbinden A, Böttger EC, Bosshard PP, Zbinden R. Evaluation of the colorimetric VITEK 2 card for identification of gram-negative nonfermenting rods: comparison to 16S rRNA gene sequencing. J Clin Microbiol. 2007;45:2270–3. http://dx.doi.org/10.1128/JCM.02604-06

30. Samuels SB, Moss CW, Weaver RE. The fatty acids of *Pseudomonas multivorans* (*Pseudomonas cepacia*) and *Pseudomonas kingii*. J Gen Microbiol. 1973;74:275–9. http://dx.doi.org/10.1099/00221287-74-2-275

31. Rodriguez-R L, Konstantinidis K. Bypassing cultivation to identify bacterial species. Microbe. 2014;9:111–8. http://dx.doi.org/10.1128/microbe.9.111.1

32. Peeters C, Meier-Kolthoff JP, Verheyde B, De Brandt E, Cooper VS, Vandamme P. Phylogenomic study of *Burkholderia glathei*-like organisms, proposal of 13 novel *Burkholderia* species and emended descriptions of *Burkholderia sordidicola, Burkholderia zhejiangensis*, and *Burkholderia grimmiae*. Front Microbiol. 2016;7:877. http://dx.doi.org/10.3389/fmicb.2016.00877

33. Meier-Kolthoff JP, Auch AF, Klenk H-P, Göker M. Genome sequence-based species delimitation with confidence intervals and improved distance functions. BMC Bioinformatics. 2013;14:60. http://dx.doi.org/10.1186/1471-2105-14-60

34. Vandamme P, Peeters C. Time to revisit polyphasic taxonomy. Antonie van Leeuwenhoek. 2014;106:57–65. http://dx.doi.org/10.1007/s10482-014-0148-x

35. Chain PS, Grafham DV, Fulton RS, Fitzgerald MG, Hostetler J, Muzny D, et al.; Genomic Standards Consortium Human Microbiome Project Jumpstart Consortium. Genomics. Genome project standards in a new era of sequencing. Science. 2009;326:236–7. http://dx.doi.org/10.1126/science.1180614

36. Holden MT, Seth-Smith HM, Crossman LC, Sebaihia M, Bentley SD, Cerdeño-Tárraga AM, et al. The genome of *Burkholderia cenocepacia* J2315, an epidemic pathogen of cystic fibrosis patients. J Bacteriol. 2009;191:261–77. http://dx.doi.org/10.1128/JB.01230-08

37. Parkhill J, Sebaihia M, Preston A, Murphy LD, Thomson N, Harris DE, et al. Comparative analysis of the genome sequences of *Bordetella pertussis, Bordetella parapertussis* and *Bordetella bronchiseptica*. Nat Genet. 2003;35:32–40 http://dx.doi.org/10.1038/ng1227

38. Stinear TP, Seemann T, Harrison PF, Jenkin GA, Davies JK, Johnson PD, et al. Insights from the complete genome sequence of *Mycobacterium marinum* on the evolution of *Mycobacterium tuberculosis*. Genome Res. 2008;18:729–41. http://dx.doi.org/10.1101/gr.075069.107

39. Fernández-González E, Bakioui S, Gomes MC, O'Callaghan D, Vergunst AC, Sangari FJ, et al. A Functional *oriT* in the Ptw Plasmid of *Burkholderia cenocepacia* Can Be Recognized by the R388 Relaxase TrwC. Front Mol Biosci. 2016;3:16. http://dx.doi.org/10.3389/fmolb.2016.00016

40. European Committee on Antimicrobial Susceptibility Testing. Antimicrobial susceptibility of *Burkholderia cepacia* complex (BCC). Stockholm: EUCAST; 2013 [cited 01 Dec 2017]. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/General_documents/BCC_susceptibility_testing_130719.pdf

41. Peeters E, Nelis HJ, Coenye T. In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim/sulfamethoxazole against planktonic and sessile *Burkholderia cepacia* complex bacteria. J Antimicrob Chemother. 2009;64:801–9. http://dx.doi.org/10.1093/jac/dkp253

42. Tseng S-P, Tsai W-C, Liang C-Y, Lin Y-S, Huang J-W, Chang C-Y, et al. The contribution of antibiotic resistance mechanisms in clinical *Burkholderia cepacia* complex isolates: an emphasis on efflux pump activity. PLoS One. 2014;9:e104986. http://dx.doi.org/10.1371/journal.pone.0104986

43. Silva IN, Ferreira AS, Becker JD, Zlosnik JE, Speert DP, He J, et al. Mucoid morphotype variation of *Burkholderia multivorans* during chronic cystic fibrosis lung infection is correlated with changes in metabolism, motility, biofilm formation and virulence. Microbiology. 2011;157:3124–37. http://dx.doi.org/10.1099/mic.0.050989-0

44. Chantratita N, Wuthiekanun V, Boonbumrung K, Tiyawisutsri R, Vesaratchavest M, Limmathurotsakul D, et al. Biological relevance of colony morphology and phenotypic switching by *Burkholderia pseudomallei.* J Bacteriol. 2007;189:807–17. http://dx.doi.org/10.1128/JB.01258-06

45. Zlosnik JE, Hird TJ, Fraenkel MC, Moreira LM, Henry DA, Speert DP. Differential mucoid exopolysaccharide production by members of the *Burkholderia cepacia* complex. J Clin Microbiol. 2008;46:1470–3. http://dx.doi.org/10.1128/JCM.02273-07

46. Bernier SP, Nguyen DT, Sokol PA. A LysR-type transcriptional regulator in *Burkholderia cenocepacia* influences colony morphology and virulence. Infect Immun. 2008;76:38–47. http://dx.doi.org/10.1128/IAI.00874-07

47. Leekitcharoenphon P, Nielsen EM, Kaas RS, Lund O, Aarestrup FM. Evaluation of whole genome sequencing for outbreak detection of *Salmonella enterica.* PLoS One. 2014;9:e87991. http://dx.doi.org/10.1371/journal.pone.0087991

48. Mahenthiralingam E, Baldwin A, Dowson CG. *Burkholderia cepacia* complex bacteria: opportunistic pathogens with important natural biology. J Appl Microbiol. 2008;104:1539–51. http://dx.doi.org/10.1111/j.1365-2672.2007.03706.x

49. Haim MS, Mollerach M, Van Domselaar G, Teves SA, Degrossi J, Cardona ST. Draft Genome Sequences of *Burkholderia contaminans* FFI-28, a strain isolated from a contaminated pharmaceutical solution. Genome Announc. 2016;4:e01177-16. http://dx.doi.org/10.1128/genomeA.01177-16

50. Baldwin A, Mahenthiralingam E, Drevinek P, Vandamme P, Govan JR, Waine DJ, et al. Environmental *Burkholderia cepacia* complex isolates from human infections. Emerg Infect Dis. 2007;13:458–61. http://dx.doi.org/10.3201/eid1303.060403

Address for correspondence: Helena M.B. Seth-Smith or Adrian Egli, Universitätsspital Basel, Division of Clinical Bacteriology and Mycology, Petersgraben 4, Basel 4031, Switzerland; email: helena.seth-smith@usb.ch or adrian.egli@usb.ch

EMERGING INFECTIOUS DISEASES®

June 2018

Zoonoses